GLP1R and type 2 diabetes mellitus: Importantly, there is presently no evidence that currently justifies the broad introduction of SGLT2 inhibitors or GLP-1 receptor agonists in early stage type 2 diabetes, although some guidelines, notably from the European Society of Cardiology, have attempted to markedly widen their recommended usage [56].